Outputs (2)

Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours (2020)
Journal Article
McCrorie, P., Mistry, J., Taresco, V., Lovato, T., Fay, M., Ward, I., Ritchie, A. A., Clarke, P. A., Smith, S. J., Marlow, M., & Rahman, R. (2020). Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours. European Journal of Pharmaceutics and Biopharmaceutics, 157, 108-120. https://doi.org/10.1016/j.ejpb.2020.10.005

Glioblastoma is a malignant brain tumour with a median survival of 14.6 months from diagnosis. Despite maximal surgical resection and concurrent chemoradiotherapy, reoccurrence is inevitable. To try combating the disease at a stage of low residual tu... Read More about Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours.

Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme (2020)
Journal Article
Greco, C., Taresco, V., Pearce, A. K., Vasey, C. E., Smith, S., Rahman, R., Alexander, C., Cavanagh, R. J., Musumeci, F., & Schenone, S. (2020). Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme. ACS Medicinal Chemistry Letters, 11(5), 657-663. https://doi.org/10.1021/acsmedchemlett.9b00530

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. Residual cells at the tumor margin are responsible for up to 85% of GBM recurrences after standard treatment. Despite this evidence, the identification of compounds active on t... Read More about Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme.